Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas
May 13, 2017 15:05 pm UTC| Business
CAMBRIDGE, Mass., May 13, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating the first achievement of efficient editing of the...
SelectMDx for Prostate Cancer Guides Patient Selection for mpMRI
May 13, 2017 13:31 pm UTC| Business
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION ABSTRACT #MP33-17 IRVINE, CA, and HERSTAL, BELGIUM - 15:30 CEST,...
May 13, 2017 12:40 pm UTC| Business
First-time data validates high levels of gene editing and reduction in serum transthyretin protein levels in rat modelsFirst to demonstrate single-dose, in vivo results using proprietary lipid nanoparticle delivery system...
May 13, 2017 03:35 am UTC| Business
NEW YORK, May 12, 2017 -- Faruqi Faruqi, LLP, a leading national securities law firm, reminds investors in Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX) of the July 11, 2017 deadline to seek the role...
May 13, 2017 03:35 am UTC| Business
NEW YORK, May 12, 2017 -- Faruqi Faruqi, LLP, a leading national securities law firm, reminds investors in Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX) of the July 11, 2017 deadline to seek the role...
May 13, 2017 02:50 am UTC| Business
NEW ORLEANS, May 12, 2017 -- Kahn Swick Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 5, 2017 to file lead plaintiff...
May 13, 2017 02:50 am UTC| Business
NEW ORLEANS, May 12, 2017 -- Kahn Swick Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 19, 2017 to file lead plaintiff...